All Congress Publications
Boehringer Ingelheim is committed to sharing knowledge with the healthcare community. Follow the links and find a variety of downloadable resources and articles with information related to Oncology.
21 - 30 of 53 results
Publications
Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.
Poster
Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Author(s): Schoeps et al.
An ongoing Phase I trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive extrapulmonary neuroendocrine carcinomas
Author(s): Gambardella et al.
Predictive response biomarkers from Phase I clinical trial of SIRPalpha inhibitor, BI 765063, stand-alone and in combination with ezabenlimab, a PD-1 inhibitor, in patients with advanced solid tumors
Author(s): Champiat et al.
Presentation
A Phase I dose escalation trial of obrixtamig + ezabenlimab in patients with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3
Author(s): Mazières et al.
DAREON®-7: Phase I open-label dose-escalation/expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas
Author(s): Capdevila et al.
Phase Ia results for systemic STING agonist BI 1703880 plus ezabenlimab in patients with advanced solid tumors: progress to date
Author(s): Parkes et al.
DAREON®-8: A Phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial
Author(s): Capdevila et al.
An open-label, Phase Ib trial of the SIRPα inhibitor BI 765063 in combination with the PD-1 inhibitor ezabenlimab and cetuximab in patients with head and neck squamous cell carcinoma
Author(s): Rojas et al.
An open-label, Phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors
Author(s): Wang et al.